Smith & Nephew plc 8% Potential Upside Indicated by Citigroup

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Smith & Nephew plc using EPIC/TICKER code (LON:SN) has had its stock rating noted as ‘Downgrades’ with the recommendation being set at ‘NEUTRAL’ this morning by analysts at Citigroup. Smith & Nephew plc are listed in the Health Care sector within UK Main Market. Citigroup have set their target price at 1700 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 8.0% from the opening price of 1574 GBX. Over the last 30 and 90 trading days the company share price has increased 344 points and decreased 306 points respectively. The 52 week high for the share price is currently at 2023 GBX while the 52 week low is 1055.01 GBX.

Smith & Nephew plc has a 50 day moving average of 1,647.22 GBX and a 200 day moving average of 1,788.84. There are currently 874,705,003 shares in issue with the average daily volume traded being 4,776,059. Market capitalisation for LON:SN is £13,327,315,920 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.
    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.
    Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook.
    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.
    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.

      Search

      Search